Memantine

Category: nootropic

Aliases: Namenda

Pharmacological Mechanism

Uncompetitive NMDA receptor antagonist with low-to-moderate affinity — preferentially blocks pathologically over-activated channels while sparing physiologic glutamate signaling. FDA-approved for moderate-to-severe Alzheimer's disease.

Half-Life (t½)

PO: 70h

Dosing Guidelines

• PO: Typical 20mg (Range: 5 - 20 mg)

Target Organ Systems

• nervous